Regulatory Q&A Forum

Ask questions, share knowledge, and get help from the regulatory community

For a U.S.-based manufacturer of a Class II Software as a Medical Device (SaMD) that processes personal health data from EU and UK users, navigating market entry involves appointing representatives fo...

💬 1 ✓ 👁️ 20 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis

As the Carbon Border Adjustment Mechanism (CBAM) enters its definitive phase in 2026, non-EU businesses importing covered goods into the EU will need representation to manage their compliance obligati...

💬 1 👁️ 13 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis

With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), how can a foreign cosmetic manufacturer establish a robust vetting process to select the most effective FDA U.S. Agent...

💬 1 👁️ 26 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis

As medical device manufacturers plan their long-term compliance strategies under the EU MDR, particularly with transitional deadlines approaching, how should they strategically evaluate and select an ...

💬 1 👁️ 24 👍 2
Asked: 1 weeks ago
Asked by Lo H. Khamis

For a sponsor preparing a 510(k) submission for a Class II Software as a Medical Device (SaMD) that processes and transmits patient data, what are the essential components of the cybersecurity documen...

💬 1 👁️ 20 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

As non-EU manufacturers prepare for the EU’s Packaging and Packaging Waste Regulation (PPWR), a common question arises regarding budgeting for compliance. However, simply asking about the cost of an E...

💬 1 👁️ 8 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

With the Modernization of Cosmetics Regulation Act (MoCRA) mandating that foreign cosmetic establishments designate a U.S. Agent, what practical framework can a company use to select a qualified and e...

💬 1 👁️ 24 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

As medical device manufacturers plan for compliance through 2026, selecting an external 'Person Responsible for Regulatory Compliance (PRRC) as a Service' is a critical strategic decision under the EU...

💬 1 👁️ 16 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

With the introduction of the EU's Packaging and Packaging Waste Regulation (PPWR), non-EU manufacturers face new compliance obligations that extend beyond traditional medical device or IVD requirement...

💬 1 ✓ 👁️ 14 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

Under the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities are required to designate a U.S. Agent to serve as their domestic point of contact for the FDA. While specific ...

💬 1 👁️ 8 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

As the interpretation of EU MDR requirements evolves, how can medical device manufacturers effectively structure and manage a "Person Responsible for Regulatory Compliance (PRRC) as a Service" relatio...

💬 1 👁️ 26 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

With the 2026 REACH registration deadline for lower-tonnage substances approaching, non-EU companies face the critical task of appointing an Only Representative (OR). Beyond simply confirming an EU le...

💬 1 👁️ 10 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis

How should manufacturers of a connected Class II device, such as an integrated continuous glucose monitoring (iCGM) system regulated under 21 CFR 862.1355, approach the documentation of a Secure Produ...

💬 1 👁️ 28 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis

Given that the Modernization of Cosmetics Regulation Act (MoCRA) mandates that foreign cosmetic product facilities designate a United States Agent, what are the key operational and strategic considera...

💬 1 ✓ 👁️ 20 👍 0
Asked: 1 weeks ago
Asked by Lo H. Khamis

When planning budgets for 2026, how should a medical device manufacturer evaluate the total cost of engaging a 'PRRC as a Service' provider under the EU MDR? Beyond a simple annual fee, what specific ...

💬 1 ✓ 👁️ 10 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis

When developing a novel Class II multiplex in vitro diagnostic (IVD) test system, such as a pharmacogenetic assessment system, how should a manufacturer navigate the interplay between general 510(k) r...

💬 1 👁️ 17 👍 2
Asked: 1 weeks ago
Asked by Lo H. Khamis

For sponsors developing sophisticated in-vitro diagnostic (IVD) devices, such as a "drug metabolizing enzyme genotyping system" (regulated under 21 CFR 862.3360) or a "pharmacogenetic assessment syste...

💬 1 👁️ 8 👍 2
Asked: 1 weeks ago
Asked by Lo H. Khamis

When a medical device manufacturer, particularly a small or medium-sized enterprise without in-house regulatory capacity, evaluates an external 'Person Responsible for Regulatory Compliance (PRRC) as ...

💬 1 👁️ 24 👍 1
Asked: 1 weeks ago
Asked by Lo H. Khamis
Showing page 3 of 54 (1079 total questions)